A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3

Dual targeting of surface receptors with bispecific antibodies is attracting increasing interest in cancer therapy. Here, we present a novel bivalent and bispecific antagonistic molecule (Dab-Fc) targeting human epidermal growth factors 2 and 3 (HER2 and HER3) derived from the Db-Ig platform, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Rau, Alexander, Kocher, Katharina, Rommel, Mirjam, Kühl, Lennart, Albrecht, Maximilian, Gotthard, Hannes, Aschmoneit, Nadine, Noll, Bettina, Olayioye, Monilola A., Kontermann, Roland E., Seifert, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993124/
https://www.ncbi.nlm.nih.gov/pubmed/33752566
http://dx.doi.org/10.1080/19420862.2021.1902034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993124/
https://www.ncbi.nlm.nih.gov/pubmed/33752566
http://dx.doi.org/10.1080/19420862.2021.1902034

Ejemplares similares